Top

Cancer Chemotherapy and Pharmacology

Published in:

01-04-2012 | Original Article

CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice

Authors: Ke-Ling Pei, Yi Yuan, San-Hai Qin, Yan Wang, Ling Zhou, Hou-Li Zhang, Xian-Jun Qu, Shu-Xiang Cui

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2012

Abstract

Purpose

Aminopeptidase N (APN/CD13) is highly expressed on the surface of cancer cells and is thought to be involved in cancer growth and metastasis. The research of APN/CD13 inhibitors is considered as a strategy of cancer treatment. We aimed to evaluate the efficacy of CIP-13F, a novel APN/CD13 inhibitor, using a Lewis lung carcinoma (LLC) implantation mouse model.

Methods

C57BL/6 mice were subcutaneously inoculated with LLC cells in anterior flank. Then, 0, 50 and 100 mg/kg of CIP-13F were injected via vena caudalis. Bestatin was used as the positive control. Administration of CIP-13F or bestatin was performed daily for 3 consecutive weeks. Mice were killed, and the tumors in anterior flank and metastasis nodules in lungs were examined. The assays of immunohistochemical staining, immunofluorescent flow cytometry and western blotting were performed to estimate the expression of APN/CD13 in LLC cells. We carried out the experiments of Annexin-V/PI staining, DNA fragmentation analysis and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining to determine apoptotic cells in LLC tissues. Using immunohistochemical staining with CD34, the antiangiogenesis of CIP-13F was evaluated in LLC tissue sections.

Results

CIP-13F treatment resulted in a significant delay of LLC growth in anterior flank. Examination of lungs showed that the number of metastatic nodules of LLC was also markedly decreased. The inhibitory effect of CIP-13F on LLC growth was further evidenced by the induction of LLC apoptosis, showing the increases in Annexin-V/PI staining cells, DNA fragmentation and TUNEL staining cells. Molecular analyses of LLC tissues in CIP-13F-treated mice suggested that the decrease in APN/CD13 expression by CIP-13F might account for its actions of mechanism. Further, the inhibition of angiogenesis in LLC tissues was determined, showing the decreases in microvessel density (MVD) and angiogenic factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and transforming growth factor-alpha (TGF-α).

Conclusion

Our results showed that CIP-13F effectively inhibited LLC growth and pulmonary metastasis in mice and suggested that CIP-13F is a potential drug for the treatment for cancers with positive APN/CD13 expression.

Firla B, Arndt M, Frank K, Thiel U, Ansorge S, Täger M, Lendeckel U (2002) Extracellular cysteines define ectopeptidase (APN, CD13) expression and function. Free Radic Biol Med 32:584–595PubMedCrossRef

Murakami H, Yokoyama A, Kondo K, Nakanishi S, Kohno N, Miyake M (2005) Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin Cancer Res 11:8674–8679PubMedCrossRef

Bank U, Bohr UR, Reinhold D, Lendeckel U, Ansorge S, Malfertheiner P, Tager M (2008) Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl and alanyl-aminopeptidase inhibitors. Front Biosci 13:3699–3713PubMedCrossRef

Reinhold D, Bank U, Täger M, Ansorge S, Wrenger S, Thielitz A, Lendeckel U, Faust J, Neubert K, Brocke S (2008) DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis. Front Biosci 13:2356–2363PubMedCrossRef

Aozuka Y, Koizumi K, Saitoh Y, Ueda Y, Sakurai H, Saiki I (2004) Antitumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16-BL6 melanoma cells orthotopically implanted into syngeneic mice. Cancer Lett 216:35–42PubMedCrossRef

Pérez I, Varona A, Blanco L, Gil J, Santaolalla F, Zabala A, Ibarguen AM, Irazusta J, Larrinaga G (2009) Increased APN/CD13 and acid aminopeptidase activities in head and neck squamous cell carcinoma. Head Neck 31:1335–1340PubMedCrossRef

Gao JJ, Gao ZH, Zhao CR, Yuan Y, Cui SX, Zhang XF, Cheng YN, Xu WF, Tang W, Qu XJ (2011) LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin. Invest New Drugs 29:574–582PubMedCrossRef

Gao JJ, Xue X, Gao ZH, Cui SX, Cheng YN, Xu WF, Tang W, Qu XJ (2011) LYP, a bestatin dimethylaminoethyl ester, inhibited cancer angiogenesis both in vitro and in vivo. Microvasc Res 82:122–130PubMedCrossRef

Cui SX, Qu XJ, Gao ZH, Zhang YS, Zhang XF, Zhao CR, Xu WF, Li QB, Han JX (2010) Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells. Cancer Lett 292:153–162PubMedCrossRef

10.

Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M (2006) Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res 12:3971–3978PubMedCrossRef

11.

Piedfer M, Dauzonne D, Tang R, N’Guyen J, Billard C, Bauvois B (2010) Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J 25:2831–2842CrossRef

12.

Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F (2008) Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer. BMC Cancer 8:74PubMedCrossRef

13.

Sakuraya M, Tamura J, Itoh K, Kubota K, Naruse T (2000) Aminopeptidase inhibitor ubenimex inhibits the growth of leukaemic cell lines and myeloma cells through its cytotoxicity. J Int Med Res 28:214–221PubMed

14.

Li Q, Fang H, Wang X, Hu L, Xu W (2009) Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation Part I. Eur J Med Chem 44:4819–4825PubMedCrossRef

15.

Wang X, Xiong XP, Lu J, Zhu GP, He SQ, Hu CS, Ying HM (2010) The in vivo study on the radiobiologic effect of prolonged delivery time to tumor control in C57BL mice implanted with Lewis lung cancer. Radiat Oncol 6:4CrossRef

16.

Liang CZ, Zhang JK, Shi Z, Liu B, Shen CQ, Tao HM (2011) Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Cancer Chemother Pharmacol. doi:10.1007/s00280-011-1699-4

17.

Qu XJ, Yang JL, Russell PJ, Goldstein D (2004) Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J Urol 172:733–738PubMedCrossRef

18.

Okutucu B, Dincer A, Habib O, Zihnioglu F (2007) Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods 70:709–711PubMedCrossRef

19.

Qi FH, Li AY, Lv H, Zhao L, Li JJ, Gao B, Tang W (2008) Apoptosis-inducing effect of cinobufacini, Bufo bufo gargarizans Cantor skin extract, on human hepatoma cell line BEL-7402. Drug Discov Ther 2:339–343

20.

Sun CC, Zhang YS, Xue X, Cheng YN, Liu HP, Zhao CR, Lou HX, Qu XJ (2011) Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma. Eur J Pharmacol 667:136–143PubMedCrossRef

21.

Inagaki Y, Tang W, Zhang L, Du G, Xu W, Kokudo N (2010) Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis. Biosci Trends 4:56–60PubMed

22.

Yamashita M, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F (2007) Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. Int J Cancer 120:2243–2250PubMedCrossRef

23.

Jullienne B, Vigant F, Muth E, Chaligné R, Bouquet C, Giraudier S, Perricaudet M, Benihoud K (2009) Efficient delivery of angiostatin K1–5 into tumors following insertion of an NGR peptide into adenovirus capsid. Gene Ther 16:1405–1415PubMedCrossRef

24.

Hausheer FH, Parker AR, Petluru PN, Jair KW, Chen S, Huang Q, Chen X, Ayala PY, Shanmugarajah D, Kochat H (2011) Mechanistic study of BNP7787-mediated cisplatin nephroprotection: Modulation of human aminopeptidase N. Cancer Chemother Pharmacol 67:381–391PubMedCrossRef

25.

Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F (2007) Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer 7:140PubMedCrossRef

26.

Mishima Y, Matsumoto-Mishima Y, Terui Y, Katsuyama M, Yamada M, Mori M, Ishizaka Y, Ikeda K, Watanbe J, Mizunuma N, Hayasawa H, Hatake K (2002) Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells. J Natl Cancer Inst 94:1020–1028PubMedCrossRef

27.

Sekine K, Fujii H, Abe F, Nishikawa K (2001) Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines. Int J Cancer 94:485–491PubMedCrossRef

28.

Santos AN, Langner J, Herrmann M, Riemann D (2000) Aminopeptidase N/CD13 is directly linked to signal transduction pathways in monocytes. Cell Immunol 201:22–32PubMedCrossRef

29.

Wickström M, Johnsen JI, Ponthan F, Segerström L, Sveinbjörnsson B, Lindskog M, Lövborg H, Viktorsson K, Lewensohn R, Kogner P, Larsson R, Gullbo J (2007) The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo. Mol Cancer Ther 6:2409–2417PubMedCrossRef

30.

Piedfer M, Dauzonne D, Tang R, N’Guyen J, Billard C, Bauvois B (2011) Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J 25:2831–2842PubMedCrossRef

31.

Cowburn AS, Sobolewski A, Reed BJ, Deighton J, Murray J, Cadwallader KA, Bradley JR, Chilvers ER (2006) Aminopeptidase N (CD13) regulates tumor necrosis factor-alpha-induced apoptosis in human neutrophils. Biol Chem 281:12458–12467CrossRef

32.

Mishima Y, Matsumoto-Mishima Y, Terui Y, Katsuyama M, Yamada M, Mori M, Ishizaka Y, Ikeda K, Watanabe J, Mizunuma N, Hayasawa H, Hatake K (2002) Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells. J Natl Cancer Inst 94:1020–1028PubMedCrossRef

33.

34.

Fukasawa K, Fujii H, Saitoh Y, Koizumi K, Aozuka Y, Sekine K, Yamada M, Saiki I, Nishikawa K (2006) Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett 243:135–143PubMedCrossRef

35.

Wang Q, Chen M, Zhu H, Zhang J, Fang H, Wang B, Xu W (2008) Design, synthesis, and QSAR studies of novel lysine derives as aminopeptidase N/CD13 inhibitors. Bioorg Med Chem 16:5473–5481PubMedCrossRef

36.

Shang L, Wang Q, Fang H, Mu J, Wang X, Yuan Y, Wang B, Xu W (2008) Novel 3-phenylpropane-1, 2-diamine derivates as inhibitors of aminopeptidase N (APN). Bioorg Med Chem 16:9984–9990PubMedCrossRef

37.

Luan Y, Xu W (2007) The structure and main functions of aminopeptidase N. Curr Med Chem 14:639–647PubMedCrossRef

Title: CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice
Authors: Ke-Ling Pei
Yi Yuan
San-Hai Qin
Yan Wang
Ling Zhou
Hou-Li Zhang
Xian-Jun Qu
Shu-Xiang Cui
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1799-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2012

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study

Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity

The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes

Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer